Literature DB >> 14614456

Induction of apoptosis in tumor cells by siRNA-mediated silencing of the livin/ML-IAP/KIAP gene.

Irena Crnkovic-Mertens1, Felix Hoppe-Seyler, Karin Butz.   

Abstract

Increased resistance to apoptosis is a hallmark of many tumor cells. The functional inhibition of specific antiapoptotic factors may provide a rational basis for the development of novel therapeutic strategies. We investigated here whether the RNA interference (RNAi) technology could be used to increase the apoptotic susceptibility of cancer cells. As a molecular target, we chose the antiapoptotic livin (ML-IAP, KIAP) gene, which is expressed in a subset of human tumors. We identified vector-borne small interfering (si)RNAs, which could efficiently block endogenous livin gene expression. Silencing of livin was associated with caspase-3 activation and a strongly increased apoptotic rate in response to different proapoptotic stimuli, such as doxorubicin, UV-irradiation, or TNFalpha. The effects were specific for Livin-expressing tumor cells. Our results (i) provide direct evidence that the intracellular interference with livin gene expression resensitizes human tumor cells to apoptosis, (ii) define the livin gene as a promising molecular target for therapeutic inhibition, and (iii) show that the livin gene is susceptible to efficient and specific silencing by the siRNA technology.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 14614456     DOI: 10.1038/sj.onc.1206973

Source DB:  PubMed          Journal:  Oncogene        ISSN: 0950-9232            Impact factor:   9.867


  24 in total

1.  siRNA targeting Livin decreases tumor in a xenograft model for colon cancer.

Authors:  Bo-Young Oh; Ryung-Ah Lee; Kwang Ho Kim
Journal:  World J Gastroenterol       Date:  2011-05-28       Impact factor: 5.742

2.  Isoform-specific silencing of the Livin gene by RNA interference defines Livin beta as key mediator of apoptosis inhibition in HeLa cells.

Authors:  Irena Crnković-Mertens; Julia Semzow; Felix Hoppe-Seyler; Karin Butz
Journal:  J Mol Med (Berl)       Date:  2005-12-31       Impact factor: 4.599

Review 3.  Delivery of intracellular-acting biologics in pro-apoptotic therapies.

Authors:  Hongmei Li; Chris E Nelson; Brian C Evans; Craig L Duvall
Journal:  Curr Pharm Des       Date:  2011       Impact factor: 3.116

4.  Proteolytic cleavage of Livin (ML-IAP) in apoptotic melanoma cells potentially mediated by a non-canonical caspase.

Authors:  Hui Yan; Brook Brouha; Tong Liu; Deepak Raj; Diana Biddle; Ray Lee; Douglas Grossman
Journal:  J Dermatol Sci       Date:  2006-06-27       Impact factor: 4.563

Review 5.  Research progress on Livin protein: an inhibitor of apoptosis.

Authors:  Biao Yan
Journal:  Mol Cell Biochem       Date:  2011-05-27       Impact factor: 3.396

6.  The effects of Livin shRNA on the response to cisplatin in HepG2 cells.

Authors:  Fangfeng Liu; Hong Chang; Wei Xu; Yunpeng Zhai
Journal:  Oncol Lett       Date:  2015-08-25       Impact factor: 2.967

Review 7.  Targeting IAP proteins for therapeutic intervention in cancer.

Authors:  Simone Fulda; Domagoj Vucic
Journal:  Nat Rev Drug Discov       Date:  2012-02-01       Impact factor: 84.694

8.  The effects on cell growth and chemosensitivity by livin RNAi in non-small cell lung cancer.

Authors:  Dong Yuan; Liqun Liu; Huaming Xu; Dayong Gu
Journal:  Mol Cell Biochem       Date:  2008-10-01       Impact factor: 3.396

9.  Livin abrogates apoptosis of SPC-A1 cell by regulating JNKI signaling pathway.

Authors:  Yu-Sheng Chen; Hong-Ru Li; Ming Lin; Gang Chen; Bao-Song Xie; Neng-Luan Xu; Li-Fang Lin
Journal:  Mol Biol Rep       Date:  2009-08-19       Impact factor: 2.316

10.  RNAi and cancer: Implications and applications.

Authors:  Maen Abdelrahim; Stephen Safe; Cheryl Baker; Ala Abudayyeh
Journal:  J RNAi Gene Silencing       Date:  2006-02-28
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.